PROTEK GROUP A LEADER IN RUSSIAN PHARMACEUTICAL MARKET
www.protek-group.ru
PROTEK GROUP A LEADER IN RUSSIAN PHARMACEUTICAL MARKET Moscow 2010 - - PowerPoint PPT Presentation
PROTEK GROUP A LEADER IN RUSSIAN PHARMACEUTICAL MARKET Moscow 2010 www.protek-group.ru IMPORTANT NOTICE (Disclaimer) Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements include
www.protek-group.ru
2
www.protek-group.ru
Matters discussed in this presentation may constitute forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events
performance, and underlying assumptions and
statements, which are
than statements
historical
words “believe”, “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project”, “will”, “may”, “might”, “should”, “could” and similar expressions (or their negative) identify certain
these forward-looking
statements include statements regarding: strategies, outlook and growth prospects; future plans and potential for future growth; liquidity, capital resources and capital expenditures; growth in demand for products; economic
and industry trends; developments
markets; the impact
regulatory initiatives; and the strength
competitors. The forward-looking statements in this presentation are based upon various assumptions, many
which are based, in turn, upon further assumptions, including without limitation, management’s examination
historical
trends, data contained in the Company’s records and
data available from third
assumptions are inherently subject to significant uncertainties and contingencies which are difficult
impossible to predict and are beyond the Company’s control and it may not achieve
accomplish these expectations, beliefs
addition, important factors that,inthe view
the Company, could cause actual results to differ materially from those discussed in the forward-looking statements include the achievement
the anticipated levels
profitability, growth, cost and its recent acquisitions, the timely development
new projects, the impact
competitive pricing, the ability to
necessary regulatory approvals, and the impact
general business and global economic
performance should not be taken as an indication
guarantee
future results, and no representation
warranty, express
implied, is made regarding future performance.
Source: audited IFRS statements
www.protek-group.ru
www.protek-group.ru
2008 revenues, RUR, million*
2009 revenues, RUR, million* Revenue growth, 2009 / 2008
* Source: audited IFRS statements
www.protek-group.ru
Company is established. Start of wholesale distribution business Launch of specialist pharmaceutical distribution
First distribution agreement with Gedeon Richter Launch of pharmaceutical production Launch of retail business Establishment of an integrated management structure Active M&A growth in retail Acquisition of O3 chain Acquisition of Protein Contour, an R&D platform Start of production
medications Commissioning of one of Europe’s largest pharmaceutical warehouse Construction of GMP compliant plant,
Distribution Retail Production Group
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 www.protek-group.ru
Group
Source: Company data
www.protek-group.ru
1.1% 1.1% 1.2% 1.5% 1.7% 1.8% 2.2% 2.8% 4.1% 1.0% 2.4% 2.8% 3.0% 3.0% 3.1% 3.1% 3.7% 6.0% 20.5% 2.0%
8
Other 81.5% 18.5%
Source: Pharmexpert preliminary data for 2009, by sales volume Source: DSM annual market report, 2009, by sales value Source: DSM annual market report, 2009, by sales value Note: Rigla market share represents the total market share of the Protek Retail segment
Other 50.4% 49.6%
CV Protek 22.2% SIA Intl 21.9% Katren 15.7% Rosta 13.2% Alliance Healthcare 9.0% Other 18.0%
36.6 Rigla (Protek) Pharmakor Implozia Raduga Stolichnye apteki Vita Doktor Stoletov Stary Lekar Pervaya Pomosch Pharmstandard Stada Valenta Sotex (Protek) Veropharm Biotek Polpharma Farm-centre Microgen Krasnogorsklek arstva
www.protek-group.ru
9
Source: Source: Company data, at the end of 2009, сities with turnover above US$1mln are reflected as of 31 December 2009. 1
2 Certified for GMP compliance by Nycomed (in relation to the licensed production of Actovegin)
Aggregate warehouse area ~ ca.168,000 sq. m (~70% is owned) Presence in all 83 regions of Russia 577 pharmacies in 25 regions of Russia and in Ukraine1 DISTRIBUTION RETAIL PRODUCTION
Warehouses
MOSCOW
Production facilities Protek pharmacies present
with annual production capacity of up to 100 mln ampoules/ 6 mln syringes/ 35 mln packs2 a year www.protek-group.ru
Commercial State / Budget (incl. DLO)
Revenue breakdown by principal customer groups
Commercial (Protek retail)
28% 22% 21% 67% 72% 72% 2007 2008 2009 5% 6% 7% 27% 22% 21% 69% 72% 72% 2007 2008 2009 4% 6% 7%
Distribution Logistics services Customs integrated clearance Marketing Information (promotion) IT services Storage services and warehouse leasing
Excellence in value added services
Source: Company data, at the end of 2009
58,041 69,256 83,121 2007 2008 2009
Total revenue dynamics
1 9 . 3 % 2 . % Total revenue, RUR mln
www.protek-group.ru * Source: audited IFRS statements
* 56 Zhivika pharmacies, owned by LLC AS-Buro Plus, in which the Company has a 25% stake and has an option to acquire additional 26% Source: Company data, at the end of 2009
www.protek-group.ru
Source: Company data, at the end of 2009 * Owned by LLC AS-Buro Plus, in which the Company has a 25% stake
Second largest pharmacy business in Russia
Total revenue dynamics
72.1% 9.2%
2 25 85 152 206 275 413 534 521 56 2001 2002 2003 2004 2005 2006 2007 2008 2009
Protek retail pharmacies Zhivika pharmacies* 5,990 10,311 11,256 2007 2008 2009 Total revenue, RUR mln
www.protek-group.ru
* Source: audited IFRS statements
Source: Company data, at the end of 2009 * Certified for GMP compliance by Nycomed (in relation to the licensed production of Actovegin)
www.protek-group.ru
Total revenue dynamics
19.8% 18.6%
Revenue breakdown (RUB mln)
Increasing share of own brands is the primary profitability driver
50% 64% 70% 37% 32% 29% 11% 4%
2%
1% 2007 2008 2009 2,453 2,938 3,484 Licensed generics Non-branded generics and substances Sotex brands Other
Source: Company data, at the end of 2009
2,453 2,938 3,484 2007 2008 2009 Total revenue, RUR mln
www.protek-group.ru
*Source: audited IFRS statements
RUR mln
Source: Company data, at the end of 2009
www.protek-group.ru
www.protek-group.ru
17
DISTRIBUTION RETAIL PRODUCTION
www.protek-group.ru
18
Performance of various sectors in Russia, 2008-2009, YoY, in RUR terms Estimated growth of pharmaceutical markets, CAGR 2008-2013, in US$ terms
Source: IMS Health Consulting 2009 Source: DSM annual market report, 2009
1 1 2 2 4 4 6 7 8 9 13 13 13 22 5 10 15 20 25 USA France UK Italy Japan Germany Canada Mexico Spain Brazil
Turkey India Russia China (%)
11% 18% Auto retail Mobile phones retail Construction Hotels, restaurants Retail GDP Utilities Agriculture Food retail Pharmaceutical market
www.protek-group.ru
www.protek-group.ru